Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cultivated oral mucosal epithelial sheet (COMET) is an autologous cell therapy developed by Seoul National University Hospital for the treatment of severe limbal stem cell deficiency (LSCD). The therapy involves harvesting a small sample of the patient's own oral mucosal tissue, which is then expanded in vitro to form a cohesive epithelial cell sheet. This sheet is surgically transplanted onto the damaged ocular surface to restore the corneal epithelium. This approach is particularly valuable for patients with bilateral LSCD, such as those suffering from Stevens-Johnson syndrome, ocular cicatricial pemphigoid, or extensive chemical burns, where autologous limbal tissue is unavailable. The transplanted cells act to reconstruct the ocular surface, reduce corneal opacity, and improve visual acuity by providing a renewable source of epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cultivated oral mucosal epithelial sheet (Seoul National University Hospital).